TITLE

Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis

AUTHOR(S)
Sfremmel, W.; Merle, U.; Zahn, A.; Autschbach, F.; Hinz, U.; Ehehalt, R.
PUB. DATE
July 2005
SOURCE
Gut;Jul2005, Vol. 54 Issue 7, p966
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: We examined the hypothesis of an anti-inflammatory effect of phosphatidylcholine in ulcerative colitis. Methods: A phase IIA, double blind, randomised, placebo controlled study was performed in 60 patients with chronic active, non steroid dependent, ulcerative colitis, with a clinical activity index (CAl) of ⩾4. Retarded release phosphatidyicholine rich phospholipids and placebo were administered at a dose of 6 g daily over three months. The primary end point was a change in CAl towards clinical remission (CAl ⩽ 3) or CAl improvement by ⩾50%. Secondary end points included ⩾50% changes in endoscopic activity index (EAl), histology, and quality of life scores. Results: Induction of clinical remission (CAl ⩽ 3) as the primary outcome variable was attained by 16 (53%) patients in the phosphatidylcholine treated group compared with three (10%) in the placebo group (p<0.00001). The rate of clinical remission and CAl improvement was 90% in the phosphatidylcholine group and only 10% in the placebo group. A median drop of seven points in the CAl score (70% improvement) was recorded in the phosphatidylchohine group compared with no change in the placebo group. Secondary end point analysis revealed concomitant drops in EAI and histology scores (p = 0.00016 and p = 0.0067 compared with placebo, respectively). Improvement in quality of life was reported by 16 of 29 evaluated patients in the phosphatidylcholine group compared with two of 30 in the placebo group (p=0.00005). Conclusion: Retarded release oral phosphatidylcholine is effective in alleviating inflammatory activity caused by ulcerative colitis.
ACCESSION #
17496266

 

Related Articles

  • Meta-Analysis of the Placebo Response in Ulcerative Colitis. Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily Levitan; Ciaran Kelly // Digestive Diseases & Sciences;Apr2008, Vol. 53 Issue 4, p875 

    Abstract   Purpose The placebo response rate in randomized controlled trials (RCTs) in ulcerative colitis (UC) varies from 0 to 76%. The aims of this study were to quantify the pooled placebo response rate and identify the factors affecting it. Methods We performed a...

  • A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. van Deventer, S. J. H.; Tami, J. A.; Wedel, M. K. // Gut;Dec2004, Vol. 53 Issue 12, p1646 

    Objective: To evaluate the safely and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule, after 1, 3, and 6 months. Methods: This was a randomised, placebo controlled, double blind, escalating dose multicentre study in 40 patients with mild...

  • Infliximab: the evidence for its place in therapy in ulcerative colitis. Assche, Gert Van; Vermeire, Séverine; Rutgeerts, Paul // Core Evidence;2007, Vol. 2 Issue 3, p151 

    Introduction: Refractory ulcerative colitis has a high, unmet medical need for avoiding steroid dependency and avoiding colectomy. Controlled trials with biologic agents have recently been reported. Aims: We aimed to review the current evidence supporting the use of the monoclonal antitumor...

  • Colon capsule endoscopy versus standard colonoscopy in assessing disease activity of ulcerative colitis: a prospective trial. Meister, T.; Heinzow, H. S.; Domagk, D.; Dortgolz, A.; Lenze, F.; Ross, M.; Domschke, W.; Lügering, A. // Techniques in Coloproctology;Dec2013, Vol. 17 Issue 6, p641 

    Background: The aim of our study was to compare colon capsule endoscopy (CCE) with standard colonoscopy (SC) in the assessment of mucosal disease activity and localization of inflammatory colonic mucosa in patients with known ulcerative colitis (UC). Methods: Thirteen symptomatic patients (8...

  • Surgery for ulcerative colitis in children. Coran, Arnold; Rivosecchi, Massimo // Pediatric Surgery International;Sep2004, Vol. 20 Issue 8, p565 

    Discusses the surgical procedure for ulcerative colitis (UC) or Crohn's disease in children. Surgical options for UC; Consideration of total proctocoletomy with rectal mucosectomy and straight ileo-anal anastomosis; Main advantages of an ileal reservoir; Problems with pouchitis; Studies of...

  • Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Higgins, P. D. R.; Schwartz, M.; Mapili, J.; Krokos, I.; Leung, J.; Zimmermann, E. M. // Gut;Jun2005, Vol. 54 Issue 6, p782 

    Background and aims: Ulcerative colitis disease activity indices offer good statistical power but small changes in these indices may not be clinically important. There are no validated definitions of remission or of significant improvement for these indices. The use of clinically important end...

  • Dramatic And Long Lasting Efficiency (13 Years) Of Oral 5 Aspirin. Maroy, Bernard // Internet Journal of Academic Physician Assistants;2003, Vol. 3 Issue 1, p12 

    Introduction: Could 5 ASA be an option in case of cortico-resistant and/or intolerant ulcerative colitis? Case report: A 55-year-old woman was referred for a recent, moderately severe, left-sided ulcerative colitis. The response to corticotherapy was initially fair, then mediocre, complicated by...

  • The Microvacular Thrombi of Colonic Tissue in Ulcerative Colitis. Guobin He; Qin Ouyang; Daiyun Chen; Fengyuan Li; Jingguo Zhou // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2236 

    Abstract  Mucosal microvacular thrombi in rectal biopsies were observed in some ulcerative colitis (UC). Heparin may be effective in steroid resistant UC in some studies, however, the new results of meta-analysis demonstrated a non-significant effect of heparin in controlled...

  • The Role of Zinc and Metallothionein in the Dextran Sulfate Sodium-Induced Colitis Mouse Model. C. Tran; S. Sundar; P. Coyle // Digestive Diseases & Sciences;Sep2007, Vol. 52 Issue 9, p2113 

    Abstract  Zinc (Zn) and its binding protein metallothionien (MT) have been proposed to suppress the disease activity in ulcerative colitis. To determine the role of Zn and MT in the dextran sulfate sodium (DSS)-induced model of colitis in mice, a DSS dose-response study was...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics